NexImmune, Inc. (NEXI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 8.59 Million USD | -80.04% |
| 2022 | 43.05 Million USD | -52.7% |
| 2021 | 91.03 Million USD | 705.52% |
| 2020 | 11.3 Million USD | -17.62% |
| 2019 | 13.71 Million USD | -3.0% |
| 2018 | 14.14 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 5.86 Million USD | -34.81% |
| 2024 Q1 | 8.99 Million USD | 4.62% |
| 2023 Q4 | 8.59 Million USD | -40.98% |
| 2023 Q3 | 14.56 Million USD | -37.97% |
| 2023 FY | 8.59 Million USD | -80.04% |
| 2023 Q1 | 30.66 Million USD | -28.79% |
| 2023 Q2 | 23.47 Million USD | -23.45% |
| 2022 Q3 | 57.67 Million USD | -12.17% |
| 2022 Q2 | 65.66 Million USD | -16.15% |
| 2022 FY | 43.05 Million USD | -52.7% |
| 2022 Q1 | 78.31 Million USD | -13.97% |
| 2022 Q4 | 43.05 Million USD | -25.34% |
| 2021 Q1 | 126.56 Million USD | 1019.95% |
| 2021 FY | 91.03 Million USD | 705.52% |
| 2021 Q4 | 91.03 Million USD | -12.92% |
| 2021 Q3 | 104.54 Million USD | -9.4% |
| 2021 Q2 | 115.39 Million USD | -8.83% |
| 2020 FY | 11.3 Million USD | -17.62% |
| 2020 Q3 | 6.69 Million USD | 0.0% |
| 2020 Q4 | 11.3 Million USD | 68.82% |
| 2019 Q4 | 13.71 Million USD | 0.0% |
| 2019 FY | 13.71 Million USD | -3.0% |
| 2018 FY | 14.14 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -2772.991% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -49.825% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | 41.518% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 72.469% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -166.893% |
| Better Therapeutics, Inc. | 22.94 Million USD | 62.542% |
| Calithera Biosciences, Inc. | 28.67 Million USD | 70.031% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -130.579% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | 58.168% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | 59.315% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 86.664% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | -265.124% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 87.895% |
| Galera Therapeutics, Inc. | 26.14 Million USD | 67.125% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -11208.869% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | 29.378% |
| Molecular Templates, Inc. | 35.38 Million USD | 75.712% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -96.586% |
| Orgenesis Inc. | 14.55 Million USD | 40.943% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | 27.182% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -6794.851% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -51.291% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -2090.853% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 98.182% |
| Statera Biopharma, Inc. | 21.16 Million USD | 59.404% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | 14.953% |
| Trevena, Inc. | 40.6 Million USD | 78.835% |
| Vaxxinity, Inc. | 44.35 Million USD | 80.624% |
| Vaccinex, Inc. | 3.63 Million USD | -136.683% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -21571.245% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 84.841% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -1446.467% |